Peter Smith‐Jones

10.4k total citations · 2 hit papers
86 papers, 7.3k citations indexed

About

Peter Smith‐Jones is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Smith‐Jones has authored 86 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Radiology, Nuclear Medicine and Imaging, 28 papers in Oncology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Smith‐Jones's work include Radiopharmaceutical Chemistry and Applications (44 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Neuroendocrine Tumor Research Advances (20 papers). Peter Smith‐Jones is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (44 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Neuroendocrine Tumor Research Advances (20 papers). Peter Smith‐Jones collaborates with scholars based in United States, Switzerland and Austria. Peter Smith‐Jones's co-authors include Steven M. Larson, Neil H. Bander, Tyson Smyth, Thomas J. Anchordoquy, Michael W. Graner, John Wongvipat, Charles L. Sawyers, Howard I. Scher, Noeen Malik and Max Kullberg and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Peter Smith‐Jones

86 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

2009 1.7k citations Chris Tran, Samedy Ouk et al. Science profile →
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes

2014 600 citations Peter Smith‐Jones et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Smith‐Jones United States	41	3.1k	2.9k	2.5k	1.9k	1.5k	86	7.3k
Ronald D. Finn United States	48	4.7k 1.5×	1.9k 0.7×	1.8k 0.7×	1.8k 1.0×	769 0.5×	176	8.2k
Adrienne H. Brouwers Netherlands	41	2.8k 0.9×	1.2k 0.4×	1.1k 0.4×	2.4k 1.3×	712 0.5×	195	5.8k
Scott T. Tagawa United States	46	3.2k 1.0×	6.3k 2.2×	2.7k 1.1×	3.9k 2.1×	2.1k 1.4×	353	10.3k
Chaitanya Divgi United States	43	3.5k 1.1×	1.8k 0.6×	1.2k 0.5×	1.6k 0.9×	583 0.4×	140	5.8k
Johannes H.A.M. Kaanders Netherlands	50	2.3k 0.7×	2.2k 0.8×	1.9k 0.8×	1.7k 0.9×	2.5k 1.7×	177	7.4k
Himisha Beltran United States	47	1.3k 0.4×	5.9k 2.0×	4.1k 1.6×	2.8k 1.5×	3.0k 2.0×	245	9.3k
Robert M. Sharkey United States	57	8.0k 2.6×	2.2k 0.8×	2.9k 1.2×	5.4k 2.9×	541 0.4×	281	12.1k
Maurizio Scaltriti United States	53	2.1k 0.7×	3.0k 1.0×	6.0k 2.4×	6.3k 3.4×	2.1k 1.4×	145	12.0k
S. Clifford Schold United States	49	1.7k 0.5×	2.5k 0.9×	2.5k 1.0×	1.8k 0.9×	1.2k 0.8×	112	9.8k
Simon P. Robinson United Kingdom	49	3.7k 1.2×	859 0.3×	2.0k 0.8×	1.2k 0.6×	1.7k 1.2×	243	8.1k

Countries citing papers authored by Peter Smith‐Jones

Since Specialization

Citations

This map shows the geographic impact of Peter Smith‐Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Smith‐Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Smith‐Jones more than expected).

Fields of papers citing papers by Peter Smith‐Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Smith‐Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Smith‐Jones. The network helps show where Peter Smith‐Jones may publish in the future.

Co-authorship network of co-authors of Peter Smith‐Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Smith‐Jones. A scholar is included among the top collaborators of Peter Smith‐Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Smith‐Jones. Peter Smith‐Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laskowski, Jennifer, Brandon Renner, Matthew C. Pickering, et al.. (2020). Complement factor H–deficient mice develop spontaneous hepatic tumors. Journal of Clinical Investigation. 130(8). 4039–4054. 49 indexed citations

Berman, Brian D., et al.. (2018). GABAA Receptor Availability Changes Underlie Symptoms in Isolated Cervical Dystonia. Frontiers in Neurology. 9. 188–188. 20 indexed citations

Carrasquillo, Jorge A., Joseph A. O’Donoghue, Volkan Beylergil, et al.. (2018). I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Research. 8(1). 20–20. 31 indexed citations

Zhang, Zhuo, Alvaro A. Ordoñez, Peter Smith‐Jones, et al.. (2017). The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography. PLoS ONE. 12(2). e0170871–e0170871. 16 indexed citations

Cheal, Sarah M., Hong Xu, Hong-Fen Guo, et al.. (2015). Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging. 43(5). 925–937. 33 indexed citations

Evans, Michael J., Peter Smith‐Jones, John Wongvipat, et al.. (2011). Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences. 108(23). 9578–9582. 247 indexed citations

Glekas, Athanasios, et al.. (2011). In Vivo Imaging of Bcr-Abl Overexpressing Tumors with a Radiolabeled Imatinib Analog as an Imaging Surrogate for Imatinib. Journal of Nuclear Medicine. 52(8). 1301–1307. 17 indexed citations

Carrasquillo, Jorge A., Neeta Pandit‐Taskar, Joseph A. O’Donoghue, et al.. (2011). ¹²⁴I-huA33 Antibody PET of Colorectal Cancer. Journal of Nuclear Medicine. 52(8). 1173–1180. 72 indexed citations

Escorcia, Freddy E., Erik Henke, Michael R. McDevitt, et al.. (2010). Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors. Cancer Research. 70(22). 9277–9286. 70 indexed citations

10.

Zhang, Hanwen, Maxim A. Moroz, Inna Serganova, et al.. (2010). Imaging Expression of the Human Somatostatin Receptor Subtype-2 Reporter Gene with ⁶⁸Ga-DOTATOC. Journal of Nuclear Medicine. 52(1). 123–131. 59 indexed citations

11.

Tran, Chris, Samedy Ouk, Nicola J. Clegg, et al.. (2009). Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science. 324(5928). 787–790. 1689 indexed citations breakdown →

12.

Krug, Lee M., Daniel T. Milton, Achim A. Jungbluth, et al.. (2007). Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels. Journal of Thoracic Oncology. 2(10). 947–952. 36 indexed citations

13.

Smith‐Jones, Peter, David B. Solit, Farzana Afroze, Neal Rosen, & Steven M. Larson. (2006). Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.. PubMed. 47(5). 793–6. 127 indexed citations

14.

Modak, Shakeel, et al.. (2005). Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 534–546. 29 indexed citations

15.

Smith‐Jones, Peter & David B. Solit. (2004). Generation of DOTA-Conjugated Antibody Fragments for Radioimmunoimaging. Methods in enzymology on CD-ROM/Methods in enzymology. 386. 262–275. 9 indexed citations

16.

Zanzonico, Pat, Mark Dunphy, Gregor J. Förster, et al.. (2004). 1094-152 Suppression of physiological myocardial fluorodeoxyglucose uptake. Journal of the American College of Cardiology. 43(5). A337–A337. 3 indexed citations

17.

Albert, Rainer, et al.. (1998). Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1, Tyr3]-octreotide (SMT487): Two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Bioorganic & Medicinal Chemistry Letters. 8(10). 1207–1210. 39 indexed citations

18.

Virgolini, Irene, Thomas Pangerl, Claudia Bischof, Peter Smith‐Jones, & Markus Peck‐Radosavljevic. (1997). Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer?. European Journal of Clinical Investigation. 27(8). 645–647. 29 indexed citations

19.

Wester, Hans‐Jürgen, Jörg Brockmann, Frank Rösch, et al.. (1997). PET-pharmacokinetics of 18F-octreotide: A comparison with 67Ga-DFO and 86Y-DTPA-octreotide. Nuclear Medicine and Biology. 24(4). 275–286. 56 indexed citations

20.

Leenders, Klaus L., Angelo Antonini, Peter Smith‐Jones, et al.. (1994). Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol.. PubMed. 43. 123–32. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact